Multiple Sclerosis, Movement Disorders & Myasthenia — Clinical Compendium

Multiple Sclerosis Dx

CNS oligodendrocyte demyelination disseminated in time and space; MRI periventricular Dawson fingers, CSF oligoclonal IgG bands; optic neuritis, INO, Lhermitte, Uhthoff.

MS Flare vs. DMTs

Acute relapse: High-dose IV Methylprednisolone (plasmapheresis if refractory). DMTs: Ocrelizumab, Natalizumab (check JC virus → PML risk!). Spasticity: Baclofen.

Neuromyelitis Optica (NMO)

Devic disease: Anti-aquaporin-4 (AQP4) IgG targeting astrocyte foot processes; bilateral optic neuritis + longitudinally extensive transverse myelitis (≥ 3 vertebral segments); brain MRI often normal.

Parkinson Disease

Loss of pigmented dopaminergic neurons in substantia nigra pars compacta + α-synuclein Lewy bodies; TRAP (pill-rolling Resting tremor, cogwheel Rigidity, Akinesia/bradykinesia, Postural instability).

Parkinson-Plus Syndromes

PSP: vertical gaze palsy (trouble looking down, frequent falls). MSA (Shy-Drager): severe orthostatic hypotension/autonomic failure + ataxia. CBD: asymmetric rigidity + alien limb phenomenon.

Essential Tremor

Autosomal dominant (50%); bilateral symmetric postural/action tremor of hands/head/voice; improves with alcohol; 1st-line Rx: Propranolol (avoid in asthma) or Primidone.

Huntington Disease

AD CAG trinucleotide repeat on chr 4p (HTT); histone deacetylation; atrophy of caudate and putamen (↓ GABA and ACh, ↑ dopamine) → hydrocephalus ex vacuo; Rx: Tetrabenazine / Deutetrabenazine (VMAT2i).

Hemiballismus & RLS

Hemiballismus: wild flinging movements from contralateral subthalamic nucleus lacunar stroke. Restless Legs Syndrome: nocturnal urge relieved by movement → check serum ferritin (iron def); Rx: Gabapentin/Pramipexole.

Neuromuscular Junction Disorders: MG vs. Lambert-Eaton

Autoimmune and infectious demyelinating disorders of the central nervous system (Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Acute Disseminated Encephalomyelitis, Progressive Multifocal Leukoencephalopathy) and peripheral nervous system (Guillain-Barré Syndrome) are distinguished by whether oligodendrocytes (CNS, upper motor neuron signs) or Schwann cells (PNS, lower motor neuron areflexia) are targeted.

Neuromuscular junction evaluation requires differentiating Myasthenia Gravis vs. Lambert-Eaton Syndrome (where Lambert-Eaton targets presynaptic voltage gated calcium channel receptors).

Feature	Myasthenia Gravis (MG)	Lambert-Eaton Myasthenic Syndrome (LEMS)
Antibody Target	Post-synaptic Nicotinic acetylcholine receptors (AChR) (85%) or MuSK	Presynaptic voltage-gated P/Q-type calcium channels (VGCC)
Muscle Use Response	Weakness fatigues and WORSENS with repetitive muscle use	Weakness IMPROVES with repetitive muscle exertion
Ocular & Bulbar Involvement	Prominent: Ptosis and diplopia (early), dysphagia, dysarthria	Spares ocular muscles; proximal lower extremity pelvic girdle weakness predominates
Autonomic Symptoms & Reflexes	Normal deep tendon reflexes; no autonomic dysfunction	Depressed/absent deep tendon reflexes; autonomic dysfunction (dry mouth, erectile dysfunction)
Malignancy Association	Thymoma (15%) or thymic follicular hyperplasia (75%); chest CT mandatory	Small Cell Lung Cancer (SCLC) (60%); paraneoplastic neuroendocrine origin
Medical Therapy	Pyridostigmine (AChE inhibitor) ± Thymectomy ± Prednisone; Plasmapheresis/IVIG in crisis	Amifampridine (3,4-DAP) or Pyridostigmine; treat underlying Small Cell Lung Carcinoma

Anterior mediastinal thymoma CT scan in autoimmune Myasthenia Gravis — **Paraneoplastic Thymoma vs. Small Cell Lung Cancer in NMJ Syndromes:** Myasthenia Gravis (post-synaptic anti-AChR antibodies) is associated with anterior mediastinal thymoma, whereas Lambert-Eaton Myasthenic Syndrome (pre-synaptic anti-P/Q VGCC antibodies) is paraneoplastic to Small Cell Lung Cancer. View Full Resolution

Multiple Sclerosis (Dissemination in Space/Time, Oligoclonal Bands & Natalizumab JC Virus PML) vs. NMOSD (Anti-Aquaporin-4)

Multiple Sclerosis (MS) is a CD4+ Th1/Th17 cell-mediated autoimmune demyelinating disease of CNS oligodendrocytes affecting women (3:1 over men) aged 20–40 living at higher northern latitudes (low Vitamin D, HLA-DRB1*15:01, EBV exposure), diagnosed by the McDonald Criteria requiring neurological lesions Disseminated in Space and Disseminated in Time. Classic presentations include Unilateral Optic Neuritis (painful monocular visual loss, central scotoma, red-color desaturation, and a Relative Afferent Pupillary Defect [Marcus Gunn pupil]), Bilateral Internuclear Ophthalmoplegia (MLF lesions), partial Transverse Myelitis (sensory level, spastic paraparesis, urinary urgency/retention, and electric-shock pain shooting down the spine on neck flexion—Lhermitte sign), cerebellar scanning speech/intention tremor/nystagmus (Charcot triad), and transient symptom worsening in hot showers/exercise (Uhthoff phenomenon). Brain and spine MRI shows periventricular white-matter plaques oriented perpendicular to the lateral ventricles ('Dawson fingers'), where active gadolinium-enhancing lesions coexist alongside non-enhancing chronic plaques (proving dissemination in time on a single scan!), and lumbar puncture shows CSF IgG Oligoclonal Bands and elevated IgG index. Treat acute MS flares with High-Dose IV Methylprednisolone (3–5 days) (or plasmapheresis if steroid-refractory; oral low-dose prednisone alone is ineffective and increases optic neuritis recurrence!). Long-term Disease-Modifying Therapies (DMTs) include Ocrelizumab (anti-CD20), Natalizumab (anti-α₄-integrin blocking leukocyte VCAM-1 transmigration across the blood-brain barrier—carries risk of fatal JC polyomavirus reactivation causing Progressive Multifocal Leukoencephalopathy [PML]!), Fingolimod (S1P receptor modulator), Dimethyl fumarate, Glatiramer, and Interferon-β. Distinguish MS from Neuromyelitis Optica Spectrum Disorder (NMOSD / Devic Disease)—driven by Anti-Aquaporin-4 (AQP4) IgG antibodies against astrocyte foot processes—which presents with simultaneous BILATERAL optic neuritis and longitudinally extensive transverse myelitis (≥3 contiguous vertebral segments on spine MRI) without Dawson fingers or oligoclonal bands.

Guillain-Barre Syndrome (Campylobacter Molecular Mimicry, Albuminocytologic Dissociation, FVC/NIF & Why Steroids Fail)

Guillain-Barré Syndrome (GBS / Acute Inflammatory Demyelinating Polyradiculoneuropathy) is an acute autoimmune attack against peripheral nervous system Schwann cells and myelin (or axonal gangliosides) occurring 1 to 3 weeks after an infection—most classically Campylobacter jejuni bloody enteritis (#1 bacterial trigger, via molecular mimicry against GM1/GD1a gangliosides), Cytomegalovirus, Epstein-Barr virus, Zika virus, or influenza/vaccination. Patients present with symmetric ASCENDING flaccid muscle weakness and paresthesias starting in the distal lower extremities and marching upward to the trunk, upper extremities, and facial nerves (bilateral facial palsy in 50%), accompanied by the diagnostic hallmark on physical exam: profound HYPO- or AREFLEXIA (absent deep tendon reflexes, 0+) and life-threatening autonomic dysreflexia/instability (labile blood pressure, arrhythmias, ileus, urinary retention). Notice the variant: Miller Fisher Syndrome (associated with Anti-GQ1b antibodies) presents with the descending triad of Ophthalmoplegia, Ataxia, and Areflexia. Lumbar puncture reveals pathognomonic Albuminocytologic Dissociation—markedly elevated CSF Protein (>45–200 mg/dL) with a NORMAL CSF White Blood Cell count (<5 cells/μL)—while nerve conduction studies show slowed conduction velocity and conduction block. CRITICAL MANAGEMENT RULES: (1) Monitor bedside pulmonary mechanics every 4 hours using Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) (do NOT rely on pulse oximetry, which stays normal until respiratory arrest is imminent!); intubate electively if FVC drops <20 mL/kg or NIF is worse than -30 cmH₂O ('20/30/40 rule'). (2) Administer either Intravenous Immunoglobulin (IVIG, 5 days) OR Plasmapheresis (Plasma Exchange) (both are equally effective; combining them offers no extra benefit). (3) Systemic Corticosteroids are COMPLETELY INEFFECTIVE and CONTRAINDICATED in Guillain-Barré Syndrome!

Movement Disorders: Parkinson vs. Huntington vs. Essential Tremor

Movement disorders are classified into hypokinetic extrapyramidal syndromes (Parkinson Disease and atypical Parkinson-plus syndromes caused by nigrostriatal dopamine depletion) and hyperkinetic syndromes (Essential Tremor, Huntington Disease, Wilson Disease, Hemiballismus, Tourette Syndrome, and Restless Legs Syndrome). Distinguishing resting vs. postural/action tremor, hereditary triplet repeat expansions, and atypical supranuclear or autonomic red flags directs targeted neuropharmacology.

Disorder	Neuropathology & Genetics	Tremor & Motor Profile	First-Line Therapy
Parkinson Disease	Loss of dopaminergic neurons in substantia nigra pars compacta; intracellular Lewy bodies containing alpha-synuclein	Resting 'pill-rolling' tremor (4–6 Hz), cogwheel rigidity, masked facies, festinating gait; improves with voluntary movement	Levodopa-Carbidopa (most effective); Dopamine agonists (Pramipexole); MAO-B inhibitors (Selegiline)
Essential Tremor	Autosomal dominant familial predisposition in 50%; exacerbated by stress and caffeine	Action / Intention tremor (worsens with sustained posture or goal-directed movement); temporarily relieved by alcohol	Propranolol (non-selective beta-blocker) OR Primidone (anticonvulsant); deep brain stimulation of VIM thalamus
Huntington Disease	Autosomal dominant CAG trinucleotide repeat expansion in HTT gene on chromosome 4; anticipation; caudate and putamen atrophy	Chorea (involuntary, irregular, dance-like jerks), motor impersistence, grimacing, progressive cognitive decline and psychosis	Tetrabenazine or Deutetrabenazine (VMAT2 inhibitors to deplete dopamine); atypical antipsychotics for psychosis

Trinucleotide repeat expansion disorders: Huntington (CAG), Fragile X (CGG), Friedreich ataxia (GAA), and Myotonic dystrophy (CTG) — **Trinucleotide Repeat Expansions & Genetic Anticipation in Movement Disorders:** Molecular genetics of trinucleotide repeat disorders (CAG in Huntington caudate atrophy, GAA in Friedreich spinocerebellar ataxia, CGG in Fragile X, CTG in Myotonic dystrophy) demonstrating paternal/maternal anticipation. View Full Resolution

Parkinson Disease (Substantia Nigra Lewy Bodies & Carbidopa-Levodopa) vs. Essential Tremor (AD, Alcohol-Responsive, Propranolol)

Boards constantly contrast the two most common tremor disorders—Parkinson Disease (PD) and Essential Tremor (ET): (1) Parkinson Disease results from degeneration of pigmented dopaminergic neurons in the substantia nigra pars compacta (losing nigrostriatal D₁ direct-pathway excitation and D₂ indirect-pathway inhibition), with surviving neurons containing eosinophilic intracytoplasmic inclusions of aggregated α-synuclein (Lewy bodies). PD presents after age 60 with the cardinal motor tetrad (TRAP): Tremor at REST (4–6 Hz asymmetric 'pill-rolling' tremor that decreases with voluntary movement/reaching), Rigidity ('cogwheel' rigidity on passive wrist/elbow movement), Akinesia/Bradykinesia (slowness of movement, micrographia, hypomimia [masked facies], hypophonia, and festinating shuffling gait with en-bloc turning), and Postural instability (late feature; Often preceded years earlier by anosmia, constipation, and REM Sleep Behavior Disorder [acting out dreams due to loss of REM atonia]). The most effective symptomatic therapy is Carbidopa-Levodopa (Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is converted by DOPA decarboxylase into dopamine; Carbidopa inhibits peripheral DOPA decarboxylase to prevent nausea/vomiting and orthostasis while maximizing CNS delivery; COMT inhibitors [entacapone] and MAO-B inhibitors [selegiline, rasagiline] block dopamine degradation, and dopamine agonists [pramipexole, ropinirole] are used in younger patients but cause impulse-control disorders). (2) Essential Tremor is the most common movement disorder overall, inherited in an Autosomal Dominant pattern in >50% of cases: it presents as a symmetric, bilateral POSTURAL and ACTION/KINETIC tremor (6–12 Hz) of the hands, head ('yes-yes' or 'no-no' titubation), and voice that is absent at rest, worsens when holding a cup/writing, and characteristially IMPROVES WITH ALCOHOL INGESTION! First-line treatment for Essential Tremor is Propranolol (non-selective beta-blocker; avoid in asthma/bradycardia) or Primidone (anticonvulsant metabolized to phenobarbital).

Parkinson-Plus Syndromes (PSP Vertical Gaze, MSA Shy-Drager, Corticobasal) & Huntington Disease (CAG Caudate Atrophy)

When a patient with parkinsonism exhibits early falls within the first year, symmetric onset, absence of resting tremor, and poor response to Levodopa, diagnose an atypical Parkinson-Plus Syndrome: (1) Progressive Supranuclear Palsy (PSP) (tauopathy) presents with early backward falls, axial rigidity, pseudobulbar affect, and pathognomonic impairment of DOWNWARD VERTICAL SACCADIC GAZE (patients cannot look down at their plate of food or stairs; midbrain atrophy produces the 'Hummingbird Sign' on sagittal MRI); (2) Multiple System Atrophy (MSA / Shy-Drager Syndrome) (α-synuclein glial cytoplasmic inclusions) presents with parkinsonism PLUS severe early autonomic failure (profound orthostatic hypotension, neurogenic bladder incontinence/retention, erectile dysfunction) and/or cerebellar ataxia; and (3) Corticobasal Degeneration (tauopathy) presents with asymmetric rigidity, apraxia, myoclonus, and the 'Alien Limb Phenomenon' (one arm moves autonomously outside voluntary control). Among hyperkinetic basal ganglia disorders: Huntington Disease is an Autosomal Dominant trinucleotide repeat disorder caused by ≥40 CAG repeats (glutamine) in the HTT (huntingtin) gene on chromosome 4p, exhibiting Anticipation (earlier age of onset and greater severity in successive generations, especially via paternal transmission during spermatogenesis). Loss of GABAergic medium spiny neurons in the Caudate and Putamen (striatum) produces hydrocephalus ex vacuo with 'boxcar-shaped' lateral ventricles on coronal MRI and the clinical triad of Choreoathetosis (writhing, dance-like involuntary movements treated with VMAT2 inhibitors Tetrabenazine, Deutetrabenazine, or Valbenazine, which deplete presynaptic monoamines), Behavioral/Psychiatric disturbances (aggression, depression, suicide), and Subcortical Dementia. Finally, sudden unilateral flinging movements of the arm and leg (Hemiballismus) localize to a lacunar stroke of the Contralateral Subthalamic Nucleus!

Multiple Sclerosis: Pathophysiology, Dissemination in Time/Space & Disease-Modifying Therapy

Multiple Sclerosis (MS) is the most common autoimmune inflammatory demyelinating disorder of the central nervous system, classically presenting in young women (20–40 years old, 3:1 female predominance) of Northern European ancestry living at high latitudes (low sunlight/vitamin D exposure, smoking, and prior Epstein-Barr Virus [EBV] infection are established risk factors, alongside HLA-DRB1*15:01 [HLA-DR2]). Autoreactive CD4⁺ Th1 and Th17 lymphocytes cross the blood-brain barrier via α₄-integrin, recognize myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG), and recruit macrophages and microglia via IFN-γ and TNF-α to destroy CNS oligodendrocytes and myelin sheaths while initially sparing axons (though chronic progressive plaques result in irreversible axonal transection and gliosis).

MS Drug / Intervention	Molecular Mechanism of Action	Clinical Indication in MS	High-Yield Board Toxicity / Monitoring Rule
IV Methylprednisolone	Glucocorticoid receptor agonist; restores blood-brain barrier & suppresses T cells	First-line for Acute MS Relapse / Optic Neuritis	Accelerates recovery speed; does NOT alter long-term disability (use Plasmapheresis if steroid-refractory)
Natalizumab	Monoclonal Ab against α₄-integrin (VLA-4) on leukocytes; blocks BBB entry	High-efficacy RRMS Disease-Modifying Therapy	JC Virus reactivation → Progressive Multifocal Leukoencephalopathy (PML); screen anti-JCV Ab
Ocrelizumab / Ofatumumab	Anti-CD20 monoclonal Ab; depletes circulating B lymphocytes	RRMS and ONLY approved drug for Primary Progressive MS (PPMS)	Infusion reactions; screen HBsAg and Anti-HBc IgG first to prevent fatal Hepatitis B reactivation
Fingolimod / Siponimod	Sphingosine-1-phosphate (S1P) receptor modulator; traps T/B cells in lymph nodes	Oral DMT for RRMS and active Secondary Progressive MS	First-dose bradycardia / AV block (6h ECG monitor), macular edema, VZV reactivation
Glatiramer Acetate / Interferon-β	Glatiramer: myelin basic protein decoy; IFN-β: downregulates MHC II & Th1 cytokines	Safe baseline DMTs (Glatiramer safe in pregnancy)	IFN-β: Flu-like myalgias, depression/suicidality, transaminitis, neutralising antibodies
Baclofen & Dalfampridine	Baclofen: GABA_B agonist; Dalfampridine: K⁺ channel blocker	Baclofen: UMN spasticity; Dalfampridine: improves walking speed	Dalfampridine is contraindicated in seizure history or moderate-to-severe renal impairment

Sagittal FLAIR Brain MRI of Multiple Sclerosis Showing Dawson Fingers — **Multiple Sclerosis Periventricular 'Dawson Fingers' MRI Plate:** Sagittal T2-FLAIR brain MRI demonstrating multiple hyperintense ovoid demyelinating plaques radiating perpendicularly from the ependymal surface of the corpus callosum and lateral ventricles along deep medullary veins ('Dawson fingers'). View Full Resolution

Classic MS Clinical Syndromes & McDonald Criteria (Dissemination in Time & Space)

The clinical hallmark of MS is neurologic deficits separated in BOTH time (multiple distinct episodes > 24 hours at least 1 month apart, OR simultaneous gadolinium-enhancing [acute] and non-enhancing [chronic] lesions on a single MRI, OR CSF oligoclonal bands) and space (lesions in ≥ 2 of 4 characteristic CNS regions: periventricular, cortical/juxtacortical, infratentorial [brainstem/cerebellum], or spinal cord). Five classic board presentations must be recognized instantly: (1) Unilateral Optic Neuritis: painful monocular visual loss, central scotoma, red-green color desaturation (dyschromatopsia), and a Marcus Gunn relative afferent pupillary defect (RAPD); (2) Internuclear Ophthalmoplegia (INO): demyelination of the Medial Longitudinal Fasciculus (MLF) causing ipsilateral adduction failure with contralateral abducting horizontal nystagmus and preserved convergence; (3) Partial Transverse Myelitis & Lhermitte Sign: asymmetric spastic paraparesis, hyperreflexia, Babinski sign, sensory level, and an electric shock-like sensation shooting down the spine and limbs upon neck flexion (Lhermitte sign) from cervical dorsal column demyelination; (4) Cerebellar Charcot Triad: scanning speech (dysarthria), intention tremor, and nystagmus (SIN); and (5) Uhthoff Phenomenon: transient, reversible worsening of baseline neurologic symptoms (e.g., blurred vision) during heat exposure, hot showers, fever, or exercise (elevated temperature slows saltatory conduction across demyelinated axons). Contrast Brain and Spine MRI is the gold standard, revealing ovoid T2/FLAIR hyperintense plaques oriented perpendicularly along medullary venules radiating from the lateral ventricles ('Dawson fingers'). Lumbar puncture shows CSF-restricted oligoclonal IgG bands on electrophoresis (present in > 90% of MS patients) and an elevated IgG index.

MS Clinical Subtypes & Acute Relapse vs. Long-Term Disease-Modifying Therapies (DMTs)

MS follows four clinical courses: Relapsing-Remitting MS (RRMS, 85–90% at onset: discrete acute attacks followed by full or partial recovery with no progression between relapses), Secondary Progressive MS (SPMS: initial RRMS that transitions after 10–20 years into steady neurologic decline), Primary Progressive MS (PPMS, 10%: steady progression from onset without distinct relapses; ocrelizumab is the ONLY FDA-approved DMT for PPMS), and Clinically Isolated Syndrome (CIS: a first single demyelinating event like optic neuritis). Acute MS Relapses (disabling new symptoms lasting > 24 hours without fever/infection; note that a urinary tract infection causing fever triggers a 'pseudo-relapse' via Uhthoff phenomenon—treat the UTI, do NOT give steroids!) are treated with high-dose intravenous Methylprednisolone (1,000 mg/day for 3–5 days), which shortens attack duration without altering long-term disability; plasmapheresis (plasma exchange) is used for severe steroid-refractory attacks. Long-term Disease-Modifying Therapies (DMTs) reduce relapse rates and new MRI lesions: (1) Ocrelizumab / Ofatumumab: humanized anti-CD20 monoclonal antibodies depleting B cells (first-line high-efficacy for RRMS and PPMS); (2) Natalizumab: monoclonal antibody against α₄-integrin (VLA-4) blocking leukocyte adhesion/transmigration across the blood-brain barrier—carries a major board risk of Progressive Multifocal Leukoencephalopathy (PML) from JC polyomavirus reactivation (contraindicated if anti-JCV antibody index is high!); (3) Fingolimod / Siponimod: sphingosine-1-phosphate (S1P) receptor modulators that sequester lymphocytes inside lymph nodes (causes first-dose bradycardia/AV block and macular edema); (4) Dimethyl fumarate (activates Nrf2 antioxidant pathway; causes flushing and lymphopenia); and (5) Glatiramer acetate (myelin basic protein decoy polymer, safe in pregnancy) and Interferon-β (flu-like symptoms, hepatotoxicity, depression).

Symptomatic Management of MS: Spasticity, Neurogenic Bladder & Walking Speed

Board questions heavily test targeted symptomatic pharmacology for chronic MS complications. (1) Upper Motor Neuron Spasticity: First-line therapy is Baclofen (a GABA_B receptor agonist in the spinal cord that inhibits monosynaptic and polysynaptic reflexes; note that abrupt withdrawal of intrathecal baclofen causes life-threatening hyperthermia, rhabdomyolysis, and seizures!) or Tizanidine (central α₂-adrenergic agonist). (2) Neurogenic Bladder (Upper Motor Neuron / Spastic Detrusor Hyperreflexia): Demyelination of suprapontine/spinal inhibitory tracts above S2–S4 removes cortical inhibition of the pontine micturition center, producing an overactive, small-capacity spastic bladder with urge incontinence, urinary frequency, and normal/low post-void residual volume (< 50–100 mL); treat with muscarinic M₃ antagonists (oxybutynin, solifenacin, tolterodine) or β₃-agonist mirabegron (or intravesical botulinum toxin). Conversely, if demyelination injures the sacral cord / conus medullaris (S2–S4) or detrusor sphincter dyssynergia occurs, the patient develops an atonic/underactive bladder with overflow incontinence and elevated post-void residual (> 150 mL), managed with clean intermittent self-catheterization (or bethanechol). (3) Gait Impairment: Dalfampridine (4-aminopyridine) blocks voltage-gated potassium (K⁺) channels exposed on demyelinated axons, prolonging action potentials and improving walking speed in MS patients. (4) Trigeminal Neuralgia in MS: Bilateral trigeminal neuralgia in a young patient is classic for MS pontine plaque; treat with carbamazepine.

Neuromyelitis Optica (NMO / Devic Disease), ADEM & Progressive Multifocal Leukoencephalopathy (PML)

Not every central nervous system white matter demyelinating lesion is Multiple Sclerosis. Board vignettes frequently present variants that can be worsened or killed by standard MS disease-modifying therapies—specifically Neuromyelitis Optica Spectrum Disorder (NMOSD / Devic disease), Acute Disseminated Encephalomyelitis (ADEM) in children, and opportunistic viral demyelination via Progressive Multifocal Leukoencephalopathy (PML).

Demyelinating Disorder	Target Cell / Pathogen & Antibody	Key Clinical Discriminator	MRI & CSF Signature	Definitive Management
Multiple Sclerosis (MS)	CNS Oligodendrocytes; CD4⁺ Th1/Th17 T cells	Young female; alert/afebrile; dissemination in time & space (optic neuritis, INO, Lhermitte)	MRI: Periventricular Dawson fingers, short cord plaques (< 2 seg); CSF: Oligoclonal IgG bands (> 90%)	Flare: IV Methylprednisolone; DMT: Ocrelizumab, Natalizumab, Fingolimod
Neuromyelitis Optica (NMO / Devic)	Astrocyte foot processes; Anti-Aquaporin-4 (AQP4) IgG	Bilateral optic neuritis + severe paraplegia + intractable hiccups/vomiting (area postrema)	Spine MRI: Longitudinally extensive myelitis ≥ 3 vertebral segments; Brain MRI often normal; CSF oligoclonal bands rare	Acute: IV steroids + Plasmapheresis; Maint: Eculizumab, Inebilizumab, Satralizumab, Rituximab
Acute Disseminated Encephalomyelitis (ADEM)	Post-viral / post-vaccine molecular mimicry; Anti-MOG IgG	Child 1–2 wk post-infection with FEVER + ENCEPHALOPATHY (somnolence/coma) + multifocal deficits; monophasic	Brain MRI: Large, bilateral, 'fluffy' white matter & thalamic lesions all of the same age	High-dose IV Methylprednisolone (± IVIG); complete recovery in most without chronic DMTs
Progressive Multifocal Leukoencephalopathy (PML)	Oligodendrocyte lysis by reactivated JC Polyomavirus	Immunocompromised (Natalizumab, Rituximab, AIDS CD4 < 200); progressive hemiparesis, aphasia, hemianopsia	MRI: Asymmetric, NON-enhancing white matter lesions with NO mass effect; CSF: JC virus PCR+	Stop Natalizumab (+ plasmapheresis) or start HIV ART to restore T-cell immunity
Guillain-Barré Syndrome (GBS / AIDP)	Peripheral Schwann cells; post-Campylobacter jejuni molecular mimicry (anti-GM1)	Ascending symmetric flaccid paralysis + AREFLEXIA + autonomic instability + bilateral CN VII palsy	CSF Albuminocytologic Dissociation (↑↑ protein with normal WBC < 5); slowed NCV	Monitor serial FVC/NIF (intubate if FVC < 20 mL/kg); IVIG or Plasmapheresis (NEVER give steroids!)

Brainstem medial longitudinal fasciculus and cranial nerve nuclei tract anatomy — **Medial Longitudinal Fasciculus (MLF) & Internuclear Ophthalmoplegia (INO) Pathway:** Demyelination of the MLF connecting the abducens nucleus (CN VI) to the contralateral oculomotor nucleus (CN III) produces ipsilateral adduction paralysis with contralateral abducting nystagmus and preserved convergence. View Full Resolution

Neuromyelitis Optica (NMO / Devic Disease): Anti-Aquaporin-4 IgG & Longitudinally Extensive Myelitis

Neuromyelitis Optica (NMO, Devic disease) is an autoimmune astrocytopathy (with secondary demyelination and necrosis) driven by a pathogenic IgG1 autoantibody against Aquaporin-4 (anti-AQP4 IgG / NMO-IgG), the principal water channel expressed heavily on astrocyte foot processes at the blood-brain barrier, optic nerves, spinal cord central gray matter, and area postrema. Unlike MS, NMO disproportionately affects non-white women (African, Asian, Latin American ancestry) and is distinguishably severe. Its three diagnostic hallmarks are: (1) Severe, often BILATERAL simultaneous optic neuritis (causing profound permanent blindness), (2) Longitudinally Extensive Transverse Myelitis (LETM)—a continuous, symmetric necrotic spinal cord lesion spanning ≥ 3 contiguous vertebral segments on spine MRI (whereas MS spinal cord plaques are short [< 1–2 segments] and asymmetric/dorsal), and (3) Area Postrema Syndrome (intractable hiccups, nausea, and vomiting from dorsal medullary floor lesions). Crucially, Brain MRI is often spared of periventricular Dawson fingers, and CSF oligoclonal bands are typically ABSENT (< 20%)! Acute attacks are treated with high-dose IV methylprednisolone and early plasmapheresis; long-term relapse prevention uses eculizumab (anti-C5), inebilizumab (anti-CD19), satralizumab (anti-IL-6R), or rituximab (note: MS drugs like interferon-β, natalizumab, and fingolimod WORSEN NMO!).

Acute Disseminated Encephalomyelitis (ADEM): Post-Viral / Post-Vaccination Monophasic Encephalopathy

Acute Disseminated Encephalomyelitis (ADEM) is an acute, monophasic autoimmune demyelinating disorder of the brain and spinal cord occurring predominantly in children (< 10 years old), typically 1 to 2 weeks after a viral upper respiratory/gastrointestinal infection (measles, varicella, enterovirus, influenza) or vaccination due to molecular mimicry against myelin oligodendrocyte glycoprotein (anti-MOG antibodies are frequently positive). The mandatory clinical discriminator separating ADEM from a first presentation of pediatric Multiple Sclerosis is acute ENCEPHALOPATHY (profound lethargy, confusion, behavioral change, somnolence, or coma) accompanied by fever, headache, meningismus, seizures, and multifocal neurologic deficits (ataxia, hemiparesis, optic neuritis)—whereas MS patients remain alert and afebrile during relapses! Brain MRI reveals large, bilateral, poorly marginated ('fluffy'), confluent T2 hyperintense lesions involving both supratentorial white matter and deep gray nuclei (thalamus/basal ganglia) that are all of the SAME radiographic age (simultaneous enhancement). Treatment is high-dose IV methylprednisolone (followed by IVIG or plasmapheresis if refractory); unlike MS, ADEM is monophasic in > 90% of patients and recovers completely without lifelong DMTs.

Progressive Multifocal Leukoencephalopathy (PML): JC Polyomavirus Reactivation

Progressive Multifocal Leukoencephalopathy (PML) is a subacute, fatal opportunistic viral demyelinating disease caused by reactivation of latent JC virus (a double-stranded circular DNA polyomavirus), which directly infects and lyses myelin-producing oligodendrocytes. PML occurs strictly in states of profound cell-mediated immunosuppression: (1) MS or Crohn patients treated with Natalizumab (α₄-integrin inhibitor), (2) AIDS patients with CD4 < 200 cells/μL, and (3) Hematologic malignancies / Rituximab / post-transplant immunosuppressants. Patients present subacutely over weeks with progressive cognitive decline, aphasia, hemiparesis, gait ataxia, and visual field defects (homonymous hemianopsia) WITHOUT fever, headache, or elevated ICP. Brain MRI is diagnostic when paired with CSF JC virus DNA PCR: PML lesions are asymmetric, multifocal subcortical white matter T2/FLAIR hyperintensities that DO NOT enhance with contrast and produce NO mass effect or midline shift (immediately distinguishing PML from cerebral toxoplasmosis and primary CNS lymphoma, both of which are ring-enhancing with mass effect!). Histopathology shows demyelination with enlarged oligodendrocyte nuclei containing glassy ground-glass viral inclusions and bizarre giant astrocytes. There is no specific antiviral cure: immediately discontinue natalizumab (perform plasmapheresis to clear the drug) or initiate Antiretroviral Therapy (ART) in HIV to restore host immunity.

Parkinson Disease Pathophysiology, Pharmacology & Parkinson-Plus Syndromes Differential

Within the basal ganglia motor loop, the substantia nigra pars compacta (SNc) projects nigrostriatal dopaminergic axons to the striatum (caudate and putamen), where dopamine binds excitatory G_s-coupled D₁ receptors (activating the Direct pathway to initiate movement) and inhibitory G_i-coupled D₂ receptors (suppressing the Indirect pathway to permit movement), while striatal acetylcholine (ACh) opposes dopamine. In Parkinson Disease (PD), progressive degeneration of pigmented dopaminergic neurons in the SNc (visible grossly as depigmentation of the midbrain substantia nigra and locus coeruleus) and accumulation of intracytoplasmic eosinophilic Lewy bodies composed of misfolded α-synuclein tip the striatal balance toward excessive cholinergic and indirect-pathway inhibition of the thalamus.

Syndrome	Aggregated Protein & Pathology	Signature Clinical Discriminator	Levodopa Response	Specific Management / Board Pearl
Idiopathic Parkinson Disease (PD)	α-Synuclein (Lewy bodies in SNc neurons); ↓ dopamine	Asymmetric pill-rolling resting tremor, cogwheel rigidity, bradykinesia, REM sleep disorder	Excellent / Robust	Levodopa-carbidopa, Pramipexole, Rasagiline, Entacapone, Amantadine (for dyskinesia)
Progressive Supranuclear Palsy (PSP)	Hyperphosphorylated Tau; dorsal midbrain atrophy ('hummingbird sign')	Vertical gaze palsy (cannot look DOWN), early backward falls, axial neck rigidity	Poor / Absent	Weighted walkers, prism glasses for downgaze; doll's eyes reflex stays intact
Multiple System Atrophy (MSA / Shy-Drager)	α-Synuclein in oligodendrocyte glial cytoplasmic inclusions	Severe early orthostatic hypotension + urinary incontinence/ED + cerebellar ataxia	Poor / Transient	Midodrine, droxidopa, fludrocortisone, compression stockings for orthostasis
Corticobasal Degeneration (CBD)	Hyperphosphorylated Tau; asymmetric frontoparietal cortex + basal ganglia	'Alien limb phenomenon', asymmetric limb apraxia, myoclonus, cortical sensory loss	None	Occupational therapy, clonazepam for myoclonus, botulinum toxin for focal dystonia
Dementia with Lewy Bodies (DLB)	α-Synuclein cortical and brainstem Lewy bodies	Dementia + visual hallucinations + fluctuating cognition WITHIN 1 yr of parkinsonism	Mild/Moderate (worsens hallucinations)	Donepezil/Rivastigmine; extreme neuroleptic sensitivity (NEVER give haloperidol!)

3D Clinical Kinematics & Motion Video Auto-Looping HD Clinical Simulation

Parkinsonian Festinating Gait, Stooped Posture & En-Bloc Turning Analysis: Clinical kinematics of nigrostriatal dopamine depletion: stooped camptocormic posture, reduced arm swing, short-stepped shuffling festination, freezing of gait, and multi-step en-bloc turning.

Parkinson Disease Cardinal Motor Signs (TRAP), Prodromal Clues & Antiparkinsonian Pharmacology

Idiopathic Parkinson Disease presents after age 60 with the cardinal TRAP tetrad: (1) Tremor at Rest: asymmetric 4–6 Hz 'pill-rolling' tremor of the hand that diminishes with voluntary movement and worsens with emotional stress; (2) Rigidity: velocity-independent 'lead-pipe' or 'cogwheel' ratchet-like resistance to passive limb movement; (3) Akinesia / Bradykinesia: slowness of movement initiation, hypomimia (masked facies), hypophonia, micrographia (progressively shrinking handwriting), and shuffling festinating gait with en-bloc turning; and (4) Postural Instability (late feature causing retropulsion and falls). Years before motor symptoms appear, patients develop REM Sleep Behavior Disorder (loss of normal REM atonia, causing patients to violently act out dreams by kicking/punching in bed), anosmia, and constipation. Levodopa-Carbidopa is the most effective symptomatic therapy: L-DOPA crosses the blood-brain barrier via large neutral amino acid transporters, while carbidopa inhibits peripheral DOPA decarboxylase (preventing peripheral conversion to dopamine, which reduces nausea/orthostasis and increases CNS L-DOPA bioavailability; long-term L-DOPA causes 'wearing-off' motor fluctuations and peak-dose choreiform dyskinesias). Adjunctive classes include: Dopamine receptor agonists (pramipexole, ropinirole, rotigotine) (cause impulse-control disorders: pathological gambling, hypersexuality, compulsive shopping, plus sleep attacks), MAO-B inhibitors (rasagiline, selegiline, safinamide) (block synaptic dopamine breakdown), COMT inhibitors (entacapone, tolcapone) (block peripheral/central methylation of L-DOPA to 3-OMD), Amantadine (increases dopamine release and blocks NMDA receptors; treats levodopa-induced dyskinesias; causes livedo reticularis and ankle edema), and Antimuscarinics (benztropine, trihexyphenidyl) (used ONLY for tremor in young patients < 60; strictly avoided in the elderly due to delirium, urinary retention, and glaucoma).

Parkinson-Plus (Atypical Parkinsonism) Syndromes: PSP vs. MSA vs. Corticobasal Degeneration

Whenever a patient presents with symmetric parkinsonism, absence of a resting pill-rolling tremor, early severe falls or autonomic collapse within the first 1–2 years, and a poor or absent response to Levodopa-Carbidopa, suspect an atypical Parkinson-Plus neurodegenerative syndrome: (1) Progressive Supranuclear Palsy (PSP): a tauopathy (hyperphosphorylated tau neurofibrillary tangles) causing midbrain atrophy ('hummingbird sign' on sagittal MRI). Its pathognomonic board hallmark is supranuclear vertical gaze palsy—specifically inability to look DOWN (patients cannot see their feet or food on a plate, walks down stairs blindly, and suffers early unprovoked backward falls, axial neck extension rigidity, and pseudobulbar affect). Note that the vestibulo-ocular reflex (doll's eyes) remains intact because the lesion is supranuclear! (2) Multiple System Atrophy (MSA, formerly Shy-Drager Syndrome): an α-synucleinopathy affecting oligodendrocytes (glial cytoplasmic inclusions) that combines parkinsonism with profound early autonomic failure (severe orthostatic hypotension [≥ 20/10 mmHg drop on standing with syncope], urinary incontinence/retention, erectile dysfunction, vocal cord stridor) AND/OR cerebellar ataxia (MSA-P vs. MSA-C; 'hot cross bun' pontine sign on MRI). (3) Corticobasal Degeneration (CBD): an asymmetric cortical and basal ganglia tauopathy presenting with striking asymmetric limb rigidity/dystonia, cortical sensory loss (astereognosis), myoclonus, ideomotor apraxia, and the 'Alien Limb Phenomenon' (one hand moves autonomously and purposefully without the patient's conscious volition, such as unbuttoning a shirt the other hand just buttoned).

Drug-Induced Parkinsonism & MPTP Toxicity

Before diagnosing neurodegenerative parkinsonism, always review the medication list for Drug-Induced Parkinsonism caused by dopamine D₂ receptor antagonists: first-generation typical antipsychotics (haloperidol, fluphenazine, chlorpromazine), high-dose atypical antipsychotics (risperidone, paliperidone), and antiemetics/prokinetics (metoclopramide, prochlorperazine, promethazine), or dopamine-depleting VMAT2 inhibitors (reserpine, tetrabenazine). Unlike idiopathic Parkinson disease (which is asymmetric and insidiously progressive), drug-induced parkinsonism is typically subacute, bilateral, and symmetric, appearing weeks to months after starting the offending agent; treatment is discontinuing the culprit drug (or switching to quetiapine, clozapine, or pimavanserin, which do not worsen parkinsonism) and administering benztropine or diphenhydramine. Additionally, young illicit drug users exposed to synthetic meperidine contaminated with MPTP (which is oxidized by glial MAO-B into the mitochondrial complex I neurotoxin MPP⁺) develop sudden, irreversible destruction of the substantia nigra pars compacta.

Hyperkinetic Movement Disorders: Essential Tremor, Huntington, Tourette, Hemiballismus & RLS

Hyperkinetic movement disorders result from disinhibition of thalamocortical motor circuits—producing involuntary rhythmic oscillations (tremor), flowing dance-like movements (chorea), violent proximal flinging (hemiballismus), sustained twisting contractions (dystonia), or suppressible semi-voluntary stereotypies (tics). Distinguishing the genetics, neuroanatomy, and first-line pharmacology of these five hyperkinetic syndromes is a core neurology board objective.

Hyperkinetic Disorder	Neuroanatomical Lesion / Genetics	Characteristic Movement & Clinical Clues	First-Line Diagnostic / Therapeutic Protocol
Essential Tremor	Autosomal dominant (50%); cerebellothalamocortical circuit oscillation	Bilateral postural/action tremor (hands, head, voice); improves with alcohol; normal tone/gait	1st-line: Propranolol (or Primidone if asthma/bradycardia); VIM thalamus DBS
Huntington Disease	AD CAG repeat (chr 4 HTT); caudate & putamen atrophy (↓ GABA, ↓ ACh, ↑ DA)	Chorea + athetosis, depression/psychosis, progressive dementia; paternal anticipation	MRI: box-like ventricles (hydrocephalus ex vacuo); Rx: Tetrabenazine / Deutetrabenazine (VMAT2i)
Hemiballismus	Lacunar stroke of CONTRALATERAL Subthalamic Nucleus (STN)	Sudden wild, violent flinging movements of unilateral proximal arm and leg	Brain MRI; Rx: Dopamine receptor blockers (Haloperidol, Risperidone) or Tetrabenazine
Tourette Syndrome	Cortico-striato-thalamo-cortical dopaminergic hyperactivity	Multiple motor tics + ≥ 1 vocal tic for > 1 year before age 18; comorbid ADHD & OCD	Behavioral (CBIT); Rx: Guanfacine / Clonidine (α₂-agonists), Aripiprazole, Tetrabenazine
Restless Legs Syndrome (RLS)	CNS iron deficiency → ↓ tyrosine hydroxylase dopaminergic activity; CKD, pregnancy	Nocturnal creeping leg discomfort + urge to move; relieved by walking	1st step: Check serum Ferritin (give iron if < 75); Rx: Gabapentin/Pregabalin or Pramipexole/Ropinirole
Wilson Disease (Hepatolenticular Degeneration)	AR ATP7B (chr 13) → copper accumulation in putamen/globus pallidus, liver, cornea	Age < 40; wing-beating tremor, dysarthria, dystonia, cirrhosis, Kayser-Fleischer rings	Dx: ↓ Ceruloplasmin, ↑ 24h urine copper; Rx: Penicillamine (+ B₆), Trientine, or Zinc

Brain MRI of Huntington Disease Showing Bilateral Caudate Atrophy — **Huntington Disease Caudate Atrophy & Hydrocephalus Ex Vacuo Plate:** Coronal and axial brain MRI in Huntington disease demonstrating severe bilateral atrophy of the heads of the caudate nuclei and putamen, resulting in loss of the normal medial convexity into the lateral ventricles and compensatory box-like ventricular dilation (hydrocephalus ex vacuo). View Full Resolution

Essential Tremor vs. Parkinsonian vs. Cerebellar Intention Tremor

Essential Tremor (ET) is the most common adult movement disorder overall, inherited in an autosomal dominant pattern with high penetrance in 50–70% of patients. Unlike Parkinson disease (which causes an asymmetric 4–6 Hz resting tremor, bradykinesia, and cogwheel rigidity), Essential Tremor presents as a bilateral, largely symmetric, high-frequency (6–12 Hz) POSTURAL and KINETIC (ACTION) tremor affecting the hands/forearms, head ('yes-yes' or 'no-no' titubation), and voice. It interferes with holding a cup, eating with a spoon, or writing (producing large, shaky, tremulous handwriting rather than Parkinsonian micrographia), disappears completely at rest, and exhibits a normal neurological exam without rigidity or bradykinesia. The pathognomonic board clue is that Essential Tremor markedly improves after drinking small amounts of alcohol (ethanol) (which potentiates central GABA_A receptors in the cerebellothalamocortical loop). First-line pharmacotherapy is Propranolol (a non-selective β₁/β₂-adrenergic blocker that blocks peripheral muscle spindle β₂ receptors and crosses the BBB; strictly contraindicated in asthma, severe COPD, or sinus bradycardia/AV block!) or Primidone (an anticonvulsant metabolized to phenobarbital and phenylethylmalonamide—preferred first-line in patients with asthma or bradycardia). Refractory disabling ET is treated with Deep Brain Stimulation (DBS) or MRI-guided focused ultrasound thalamotomy of the Ventral Intermediate (VIM) nucleus of the thalamus. By contrast, a Cerebellar Intention Tremor is a low-frequency (2–4 Hz) zig-zag oscillation that crescendos specifically as the limb approaches a visual target (finger-to-nose dysmetria), accompanied by ataxia and nystagmus.

Huntington Disease (CAG Repeat, Caudate Atrophy) vs. Hemiballismus (Subthalamic Nucleus)

Huntington Disease (HD) is an autosomal dominant neurodegenerative disorder caused by an unstable CAG trinucleotide repeat expansion (≥ 40 repeats) in the HTT (huntingtin) gene on chromosome 4p. Mutant polyglutamine huntingtin protein aggregates inside neurons, causing histone deacetylation (transcriptional silencing) and NMDA-mediated glutamate excitotoxicity. Because CAG repeat expansion is unstable during spermatogenesis, HD exhibits dramatic anticipation in paternal transmission (offspring develop symptoms at a much younger age with larger repeat numbers). Neuropathologically, selective destruction of GABAergic medium spiny neurons (and cholinergic interneurons) in the striatum (caudate nucleus and putamen) removes inhibition of the indirect pathway, resulting in a hyperdopaminergic state. Coronal Brain MRI/CT demonstrates profound bilateral atrophy of the caudate heads, flattening the lateral walls of the frontal horns and producing box-like enlargement of the lateral ventricles (hydrocephalus ex vacuo). Patients present at age 30–50 with the triad of chorea (continuous, irregular, writhing dance-like movements and athetosis), behavioral/psychiatric disturbances (depression, suicidality, aggression, psychosis), and progressive subcortical dementia. Symptomatic chorea is treated with vesicular monoamine transporter 2 (VMAT2) inhibitors—Tetrabenazine, Deutetrabenazine, or Valbenazine (which deplete presynaptic dopamine vesicles) or dopamine receptor antagonists (haloperidol, olanzapine, risperidone). Separately, Hemiballismus consists of sudden, violent, high-amplitude flinging movements of the proximal arm and leg on ONE side of the body, caused by a lacunar ischemic stroke (or nonketotic hyperglycemia) damaging the CONTRALATERAL Subthalamic Nucleus (STN) (loss of STN glutamate excitation of the globus pallidus internus disinhibits the ipsilateral thalamus, firing to the contralateral body; treat with haloperidol or tetrabenazine).

Tourette Syndrome vs. Restless Legs Syndrome (Ferritin Workup) & Wilson Disease

Tourette Syndrome is a childhood-onset neurodevelopmental disorder (mean onset 6–8 years, 4:1 male predominance, strongly comorbid with ADHD and Obsessive-Compulsive Disorder [OCD]). DSM-5 diagnostic criteria require BOTH multiple motor tics (blinking, grimacing, shoulder shrugging) AND at least one vocal/phonic tic (throat clearing, grunting, sniffing, or coprolalia [< 15%]), persisting for > 1 year with onset before age 18. First-line behavioral therapy is Comprehensive Behavioral Intervention for Tics (CBIT / habit reversal therapy); first-line pharmacotherapy for mild-to-moderate tics (especially with comorbid ADHD) is α₂-adrenergic agonists (Guanfacine or Clonidine), while severe disabling tics are treated with VMAT2 inhibitors (Tetrabenazine/Deutetrabenazine) or dopamine D₂ antagonists (Aripiprazole, Risperidone, Fluphenazine, Pimozide). Restless Legs Syndrome (Willis-Ekbom Disease) is a sensorimotor disorder characterized by an irresistible urge to move the legs accompanied by creeping/crawling dysesthesias that begin or worsen during evening/nighttime rest and are immediately relieved by walking or stretching. Because brain iron is an essential cofactor for tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis), the mandatory initial diagnostic test in every RLS patient is a serum ferritin level! If serum ferritin is < 75 ng/mL, treat with oral iron repletion; if iron stores are normal, first-line medical therapy is gabapentin / pregabalin (α₂δ calcium channel ligands) or dopamine agonists (pramipexole, ropinirole). Finally, in any patient under age 40 presenting with a 'wing-beating' tremor, dysarthria, dystonia, parkinsonism, psychiatric changes, and elevated LFTs, immediately screen for Wilson Disease (autosomal recessive ATP7B mutation on chromosome 13 impairing hepatocyte copper excretion into bile and incorporation into ceruloplasmin: low serum ceruloplasmin, high 24-hour urinary copper, slit-lamp Kayser-Fleischer corneal rings, and lentiform nucleus T2 hyperintensity; treat with penicillamine, trientine, or zinc).

COMLEX / OMM Integration NBOME High-Yield Correlate

Neuromuscular, Bladder & Axial Biomechanics, Autonomics & OMT in MS / Parkinson Disease

Neurogenic Bladder Autonomics (MS & Transverse Myelitis): The urinary bladder is regulated by sympathetic fibers from T12–L2 (via the inferior mesenteric and hypogastric nerves, which relax the detrusor [β₃] and contract the internal urethral sphincter [α₁] to promote urine storage) and parasympathetic pelvic splanchnic fibers from S2–S4 (which contract the detrusor [M₃] to promote voiding). In Multiple Sclerosis with suprasacral cord plaques, loss of descending inhibition creates a spastic hyperreflexic bladder; osteopathic treatment of the sacrum and lumbosacral junction, alongside bladder anterior Chapman point inhibition (periumbilical region) and posterior Chapman point release (transverse process of L2), helps modulate viscerosomatic tone.
Thymus & Thoracic Inlet in Myasthenia Gravis: In Myasthenia Gravis (associated with thymic hyperplasia or thymoma), the thymus receives sympathetic innervation from T1–T4. Opening the thoracic inlet (Sibson fascia) and applying thoracic lymphatic pump techniques enhance lymphatic clearance of autoantibodies and improve diaphragmatic excursion.
Parkinsonian Stooped Posture, Festination & OMT Protocol: Patients with Parkinson disease exhibit severe flexor muscle predominance: hypertonicity of the pectoralis minor, sternocleidomastoid, rectus abdominis, iliopsoas, and hamstrings, producing a stooped thoracic kyphosis, forward head posture, and shuffling festinating gait with reduced rib cage compliance. Muscle Energy Technique (MET), gentle articulatory techniques, psoas counterstrain (F S_TowardR_Away), and rib raising / doming the diaphragm significantly improve stride length, postural balance, and pulmonary vital capacity.
Contraindications in Neurodegenerative & Demyelinating Disease: Cervical HVLA is contraindicated in elderly Parkinson patients with advanced cervical spondylosis or severe axial rigidity; additionally, avoid hyperthermic environments or vigorous heat packs in Multiple Sclerosis because raising core body temperature precipitates transient conduction block (Uhthoff phenomenon).

Board Traps & Common Distractors

Natalizumab & JC Virus PML Trap: Before starting or continuing Natalizumab (α₄-integrin inhibitor) in a patient with Multiple Sclerosis, always check anti-JC virus antibody status; progressive subacute hemiparesis, visual loss, or cognitive decline with a NON-enhancing white matter lesion on MRI indicates Progressive Multifocal Leukoencephalopathy (PML)—stop natalizumab immediately!
MS Pseudo-Relapse (Uhthoff Phenomenon) vs. True Relapse: A patient with Multiple Sclerosis who experiences sudden worsening of baseline old neurologic deficits during a fever, urinary tract infection, or hot weather has a 'pseudo-relapse' (Uhthoff phenomenon); treat the underlying infection and cool the patient—do NOT administer high-dose IV corticosteroids!
Propranolol Contraindication in Essential Tremor with Asthma: While Propranolol is a first-line agent for Essential Tremor, non-selective beta-blockade triggers life-threatening bronchospasm in patients with asthma or severe COPD; always select Primidone as first-line therapy in asthmatic patients.
Guillain-Barré Syndrome Respiratory Monitoring & Steroid Trap: In Guillain-Barré Syndrome (ascending paralysis with areflexia and CSF albuminocytologic dissociation), the #1 cause of death is neuromuscular respiratory failure; monitor serial Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF)—NOT pulse oximetry!—and intubate if FVC drops below 20 mL/kg. Furthermore, treat with IVIG or Plasmapheresis (corticosteroids are ineffective and contraindicated in GBS!).
Myasthenic Crisis vs. Cholinergic Crisis Management: In a patient with Myasthenia Gravis presenting with acute bulbar weakness and respiratory failure, stop all anticholinesterases (pyridostigmine) and secure the airway (intubate if FVC < 20 mL/kg or NIF worse than −30 cm H₂O) before initiating Plasmapheresis or IVIG; never administer aminoglycosides, fluoroquinolones, beta-blockers, or IV magnesium, which precipitate crisis.
Restless Legs Syndrome Iron Deficiency Workup: Never initiate a dopamine agonist (pramipexole) for Restless Legs Syndrome without first measuring a serum ferritin level; iron deficiency impairs CNS tyrosine hydroxylase and is a reversible primary cause of RLS.

Previous Chapter • Vol 2: Clinical Ch. 32

Headaches, Trigeminal Neuralgia & Cranial Nerve Palsies

Vol 2: Clinical Ch. 34 • Next Chapter

Cognitive Decline

Table of Contents (105 Chapters) Volume 2: Organ System Clinical Pathology • Chapter 33 of 60